Emergent BioSolutions (NYSE:EBS) Shares Down 3.9% – Here’s What Happened

Emergent BioSolutions Inc. (NYSE:EBS) fell 3.9% on Tuesday . The company traded as low as $10.78 and last traded at $10.75. 113,481 shares traded hands during trading, a decline of 89% from the average session volume of 992,138 shares. The stock had previously closed at $11.19.

Analyst Ratings Changes

Several analysts recently issued reports on EBS shares. Benchmark boosted their price objective on shares of Emergent BioSolutions from $8.00 to $12.00 and gave the company a “buy” rating in a report on Thursday, November 7th. StockNews.com downgraded shares of Emergent BioSolutions from a “buy” rating to a “hold” rating in a research note on Friday, January 24th. Finally, HC Wainwright reissued a “buy” rating and issued a $15.00 price objective on shares of Emergent BioSolutions in a research report on Tuesday, January 21st.

Emergent BioSolutions Stock Up 2.6 %

The business has a 50-day simple moving average of $9.54 and a two-hundred day simple moving average of $9.33. The company has a debt-to-equity ratio of 1.30, a quick ratio of 1.47 and a current ratio of 2.88. The company has a market capitalization of $600.59 million, a price-to-earnings ratio of -2.69 and a beta of 1.60.

Emergent BioSolutions (NYSE:EBS) last released its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $1.37 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.49 by $0.88. The firm had revenue of $293.80 million during the quarter, compared to analysts’ expectations of $328.72 million. Emergent BioSolutions had a negative return on equity of 9.91% and a negative net margin of 18.55%. During the same quarter in the prior year, the business posted ($1.44) earnings per share. As a group, equities analysts predict that Emergent BioSolutions Inc. will post -0.63 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Allspring Global Investments Holdings LLC acquired a new position in shares of Emergent BioSolutions in the fourth quarter valued at approximately $1,831,000. Assenagon Asset Management S.A. lifted its stake in shares of Emergent BioSolutions by 3.4% during the 4th quarter. Assenagon Asset Management S.A. now owns 766,537 shares of the biopharmaceutical company’s stock worth $7,328,000 after purchasing an additional 24,985 shares during the period. B. Riley Wealth Advisors Inc. acquired a new stake in shares of Emergent BioSolutions during the third quarter worth $295,000. Barclays PLC boosted its holdings in shares of Emergent BioSolutions by 361.6% during the third quarter. Barclays PLC now owns 39,308 shares of the biopharmaceutical company’s stock worth $329,000 after purchasing an additional 30,792 shares during the last quarter. Finally, Oak Hill Advisors LP purchased a new stake in shares of Emergent BioSolutions in the third quarter valued at $9,296,000. 78.40% of the stock is currently owned by institutional investors and hedge funds.

About Emergent BioSolutions

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.